Company Expects FY26 Adjusted EBITDA of $95M-$98M
Sees FY26 adjusted EBITDA $95M-$98M. Free cash flow is expected to be positive for FY26, excluding the impact of any potential legal settlements. Calafiore added, "As we move into 2026, our priorities remain centered on expanding market penetration, accelerating adoption of enabling technologies, such as 7D FLASH Navigation, and advancing commercial execution. With full-year contributions from the TRUELOK Elevate System and the FITBONE Bone Transport and Trochanteric Lengthening Nails, the planned second-half full launch of VIRATA, continued Spine commercial channel optimization, a renewed focus on advancing our Biologics portfolio, and sustained momentum across our Limb Reconstruction and BGT businesses, we believe the Company is well-positioned to deliver durable top-line growth, expanding margins, and strong free cash flow that supports long-term shareholder value."
